{
    "clinical_study": {
        "@rank": "82421", 
        "arm_group": [
            {
                "arm_group_label": "dabigatran"
            }, 
            {
                "arm_group_label": "warfarin"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct\n      comparative safety and effectiveness studies of dabigatran and warfarin using real world\n      data from Humana's health plan operations."
        }, 
        "brief_title": "The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "Study Design:\n\n      n/a"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patient must have at least one inpatient, one physician office visit, or one\n             emergency room visit with a diagnosis of AF on the index date or during the pre-index\n             period.\n\n          -  Patients must be continuously enrolled in a health plan during the pre-index period\n\n          -  Patient must have a prescription for dabigatran or warfarin\n\n          -  Patient must be treatment naive from all oral anticoagulant (OAC) use prior to first\n             OAC prescription\n\n          -  Aged 18-89 years on the index date.  The index date is defined as the date of the\n             first OAC prescription\n\n        Exclusion criteria:\n\n          -  Diagnosis of hyperthyroidism during the pre-index period,\n\n          -  Having claims for any of the following within 3 months prior to the first diagnosis\n             of AF: cardiac surgery, pericarditis, myocarditis, pulmonary embolism.\n\n          -  Any patients with at least one medical claim for valvular heart disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "NVAF"
            }
        }, 
        "enrollment": {
            "#text": "20000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061748", 
            "org_study_id": "1160.192"
        }, 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky"
                }, 
                "name": "1160.192.01 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061748"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ischemic stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Hemorrhagic stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major intracranial bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major extracranial bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major GI bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major upper GI bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major lower GI bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major urogenital bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major other bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Transient Ischemic Attack", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Myocardial Infarction", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Venous Thromboembolism", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Deep Vein Thrombosis", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Pulmonary Embolism", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}